Heron Therapeutics, Inc. (HRTX) stock
HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.28−0.00 (-0.74%)
Close on Nov 17, 2026Market cap $53.58MP/E –Yield –
Heron Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Heron Therapeutics's total assets was $252.26M at Jun 30, 2026. For fiscal 2025 it was $255.88M, up 9.7% from the year before. Over ten years it grew 6.4% a year on average. The highest annual figure on record is $512.78M in fiscal 2019.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $255.88M | +9.7% |
| FY2024 | Dec 31, 2024 | $233.15M | +4.8% |
| FY2023 | Dec 31, 2023 | $222.51M | -11.3% |
| FY2022 | Dec 31, 2022 | $250.95M | -17.9% |
| FY2021 | Dec 31, 2021 | $305.71M | -13.5% |
| FY2020 | Dec 31, 2020 | $353.56M | -31.1% |
| FY2019 | Dec 31, 2019 | $512.78M | +10.9% |
| FY2018 | Dec 31, 2018 | $462.18M | +97.3% |
| FY2017 | Dec 31, 2017 | $234.31M | +247.2% |
| FY2016 | Dec 31, 2016 | $67.48M | -51.0% |
| FY2015 | Dec 31, 2015 | $137.85M | +79.8% |
| FY2014 | Dec 31, 2014 | $76.68M | +1.0% |
| FY2013 | Dec 31, 2013 | $75.94M | +35.7% |
| FY2012 | Dec 31, 2012 | $55.97M | +187.8% |
| FY2011 | Dec 31, 2011 | $19.45M | +568.0% |
| FY2010 | Dec 31, 2010 | $2.91M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $252.26M | +8.7% |
| Q1 FY2026 | Mar 31, 2026 | $246.22M | +4.4% |
| Q4 FY2025 | Dec 31, 2025 | $255.88M | +9.7% |
| Q3 FY2025 | Sep 30, 2025 | $248.95M | +12.8% |
| Q2 FY2025 | Jun 30, 2025 | $232.09M | +6.4% |
| Q1 FY2025 | Mar 31, 2025 | $235.75M | +8.2% |
| Q4 FY2024 | Dec 31, 2024 | $233.15M | +4.8% |
| Q3 FY2024 | Sep 30, 2024 | $220.78M | -3.7% |
| Q2 FY2024 | Jun 30, 2024 | $218.14M | +8.4% |
| Q1 FY2024 | Mar 31, 2024 | $217.89M | -1.4% |
| Q4 FY2023 | Dec 31, 2023 | $222.51M | -11.3% |
| Q3 FY2023 | Sep 30, 2023 | $229.20M | -15.7% |
| Q2 FY2023 | Jun 30, 2023 | $201.22M | -17.5% |
| Q1 FY2023 | Mar 31, 2023 | $220.88M | -19.3% |
| Q4 FY2022 | Dec 31, 2022 | $250.95M | -17.9% |
| Q3 FY2022 | Sep 30, 2022 | $271.95M | -22.8% |
| Q2 FY2022 | Jun 30, 2022 | $243.97M | -39.6% |
| Q1 FY2022 | Mar 31, 2022 | $273.72M | -12.0% |
| Q4 FY2021 | Dec 31, 2021 | $305.71M | -13.5% |
| Q3 FY2021 | Sep 30, 2021 | $352.39M | -9.6% |
| Q2 FY2021 | Jun 30, 2021 | $404.25M | -6.6% |
| Q1 FY2021 | Mar 31, 2021 | $310.93M | -35.1% |
| Q4 FY2020 | Dec 31, 2020 | $353.56M | -31.1% |
| Q3 FY2020 | Sep 30, 2020 | $390.02M | -0.7% |
| Q2 FY2020 | Jun 30, 2020 | $432.72M | +5.1% |
| Q1 FY2020 | Mar 31, 2020 | $478.94M | +9.9% |
| Q4 FY2019 | Dec 31, 2019 | $512.78M | +10.9% |
| Q3 FY2019 | Sep 30, 2019 | $392.96M | -16.6% |
| Q2 FY2019 | Jun 30, 2019 | $411.67M | -19.4% |
| Q1 FY2019 | Mar 31, 2019 | $435.79M | +137.6% |
| Q4 FY2018 | Dec 31, 2018 | $462.18M | +97.3% |
| Q3 FY2018 | Sep 30, 2018 | $470.90M | +298.4% |
| Q2 FY2018 | Jun 30, 2018 | $510.56M | +258.6% |
| Q1 FY2018 | Mar 31, 2018 | $183.38M | -3.3% |
| Q4 FY2017 | Dec 31, 2017 | $234.31M | +247.2% |
| Q3 FY2017 | Sep 30, 2017 | $118.20M | +19.6% |
| Q2 FY2017 | Jun 30, 2017 | $142.37M | – |
| Q1 FY2017 | Mar 31, 2017 | $189.56M | – |
| Q4 FY2016 | Dec 31, 2016 | $67.48M | – |
| Q3 FY2016 | Sep 30, 2016 | $98.81M | – |
See a number that looks wrong?